STCube

STCube EBITDA Margin

The EBITDA Margin of STCube (052020.KQ) as of Oct 24, 2026 is -336.09 %. In the previous year, EBITDA Margin was -190.36 % — a change of 76.56% (lower).

EBITDA Margin

-336.09 %

YoY

76.56%

Last updated:

EBITDA Margin of STCube is 2025 -336.09 % . EBITDA Margin of STCube was 2024 -190.36 % . It decreases by 76.56% lower compared to the previous year.

The STCube EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2018
-102.32 KRW
Jan 1, 2019
-49.10 KRW
Jan 1, 2020
-117.93 KRW
Jan 1, 2021
-230.91 KRW
Jan 1, 2022
-287.99 KRW
Jan 1, 2023
-431.14 KRW
Jan 1, 2024
-190.36 KRW
Jan 1, 2025
-336.09 KRW
The STCube EBITDA Margin history
YEAREBITDA MarginYoY
-336.09 %+76.56%
-190.36 %-55.85%
-431.14 %+49.71%
-287.99 %+24.72%
-230.91 %+95.80%
-117.93 %+140.17%
-49.10 %-52.01%
-102.32 %-37.19%
-162.91 %+1,055.86%
-14.09 %-84.39%
-90.29 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

STCube Stock analysis

What does STCube do? STCube Inc. generates revenue through its two business segments. The IT segment distributes CCTV lenses and related components, targeting businesses requiring security solutions. The BT segment develops and licenses immunomodulatory anticancer drug therapeutic candidates, selling to pharmaceutical companies and research institutions. Both segments operate under the company's brand, leveraging its IT and biotechnology expertise. The IT segment focuses on closed-circuit television lens distribution, serving commercial and industrial clients seeking reliable security infrastructure. The BT segment's drug development and licensing activities cater to the pharmaceutical industry, providing innovative therapeutic candidates for cancer treatment. These offerings align with STCube's dual expertise in technology and biotechnology. STCube's revenue streams are derived from product distribution in the IT sector and licensing agreements in the biotechnology sector. The company's clients include businesses needing CCTV components and pharmaceutical firms interested in anticancer drug development. This dual approach allows STCube to serve distinct market segments with specialized solutions. STCube is one of the most popular companies on Eulerpool.

Frequently Asked Questions about STCube stock

EBITDA Margin of STCube is -336.09 % in 2025.

EBITDA Margin of STCube changed from -190.36 % to -336.09 %, representing a 76.56% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin STCube since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's STCube with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — STCube

All Key Metrics — STCube